Q: What is Voydeya used for?

Voydeya is used to treat paroxysmal nocturnal hemoglobinuria with ongoing anemia due to extravascular hemolysis (as add-on to ravulizumab or eculizumab ).

Q: How does Voydeya work?

Mechanism of Action Voydeya belongs to a class of medicines called complement factor D inhibitors. It is designed to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder where the immune system attacks and destroys red blood cells. The drug targets a specific part of the immune system known as the complement system. This system is a group of proteins that usually help the body fight infections. In people with PNH, the complement system becomes overactive and destroys red blood cells. Targeting Factor D Voydeya specifically blocks an enzyme called factor D. This enzyme plays a key role in the alternative pathway of the complement system. By inhibiting factor D, the medication helps stop the chain reaction that leads to the destruction of red blood cells. Preventing Red Blood Cell Breakdown Many patients with PNH already take medications known as C5 inhibitors that prevent red blood cells from breaking apart inside the blood vessels. However, some of these patients still experience extravascular hemolysis, which is when red blood cells are destroyed outside the blood vessels, typically in the spleen or liver. Voydeya is used as an add-on treatment to address this specific problem. By blocking the complement system at an earlier stage, it helps prevent the immune system from marking red blood cells for destruction in the liver or spleen, which helps improve red blood cell counts and reduce symptoms like anemia.

Q: What are the active ingredients in Voydeya?

The active ingredient in Voydeya is danicopan .

Q: What are the side effects of Voydeya?

Common side effects of Voydeya may include: Headache Nausea Diarrhea Joint pain (arthralgia) Pain in the arms or legs Fever Voydeya can cause serious health complications that require immediate medical attention. These include: Serious Infections: This medication affects a part of the immune system, increasing the risk of life-threatening meningococcal infections. Seek emergency care if you experience a high fever, headache with a stiff neck, confusion, or a rash. Liver Problems: Voydeya can cause an increase in liver enzymes, which may indicate liver stress or damage. Healthcare providers typically monitor liver function through regular blood tests during treatment. Allergic Reactions: Although rare, serious allergic reactions can occur. Symptoms may include hives, swelling of the face or throat, and difficulty breathing. This is not a complete list of potential side effects. Patients should report any new or worsening symptoms to their healthcare provider. Always consult with a healthcare professional about potential side effects.

Q: What drug class is Voydeya?

Voydeya belongs to the IGF-1 receptor antagonist drug class.

Q: What is the dosage of Voydeya and how do I take it?

Administration Instructions Voydeya is a tablet taken by mouth. It is typically taken three times a day, with or without food. When taking this medication: Swallow the tablets whole. Do not crush, chew, or break the tablets. Voydeya is used as an add-on therapy alongside other specific medications. Continue taking all medications in your treatment plan as directed by your healthcare provider. Missed Dose If you miss a dose, take it as soon as you remember. If it is nearly time for your next scheduled dose, skip the missed dose and resume your normal schedule. Do not take extra medicine to make up for a missed dose.

Q: What forms and strengths does Voydeya come in?

Available Forms Voydeya is supplied as film-coated tablets for oral administration. These tablets are intended to be swallowed whole. The medication is produced in different strengths, which are distinguished by their physical appearance, including color and specific markings on the tablet surface.

Q: What is the FDA approval status of Voydeya?

FDA Approval and Indication The U.S. Food and Drug Administration (FDA) approved Voydeya (danicopan) in March 2024. It is indicated as an add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria (PNH). Boxed Warning Voydeya carries a boxed warning regarding the risk of serious and life-threatening infections caused by encapsulated bacteria, such as Streptococcus pneumoniae , Neisseria meningitidis , and Haemophilus influenzae type b. These infections can become fatal if not identified and treated quickly. Healthcare providers must ensure patients are vaccinated against these bacteria before starting treatment. REMS Program Due to the risk of serious infections, Voydeya is available only through a restricted program called the Voydeya Risk Evaluation and Mitigation Strategy (REMS). Requirements of this program include: Prescribers must be certified by enrolling in the Voydeya REMS program. Patients must be vaccinated against specific bacteria according to current medical guidelines at least two weeks before their first dose. Patients must be informed of the signs of serious infection and must carry a Patient Safety Card at all times to alert medical professionals that they are taking this medication.

Question 1

What is Voydeya?

Accepted Answer

Voydeya is a medication known as a complement inhibitor that specifically targets Factor D, a protein within the body's immune system. By inhibiting this protein, the drug helps regulate the alternative complement pathway to prevent the premature destruction of red blood cells.

This therapy is intended for use alongside other specific complement inhibitors. It provides an additional method of control for red blood cell breakdown when primary treatments are not sufficient on their own.

Question 2

What is Voydeya used for?

Accepted Answer

Voydeya is used to treat paroxysmal nocturnal hemoglobinuria with ongoing anemia due to extravascular hemolysis (as add-on to ravulizumab or eculizumab).

Question 3

How does Voydeya work?

Accepted Answer

Mechanism of Action

Voydeya belongs to a class of medicines called complement factor D inhibitors. It is designed to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder where the immune system attacks and destroys red blood cells.

The drug targets a specific part of the immune system known as the complement system. This system is a group of proteins that usually help the body fight infections. In people with PNH, the complement system becomes overactive and destroys red blood cells.

Targeting Factor D

Voydeya specifically blocks an enzyme called factor D. This enzyme plays a key role in the alternative pathway of the complement system. By inhibiting factor D, the medication helps stop the chain reaction that leads to the destruction of red blood cells.

Preventing Red Blood Cell Breakdown

Many patients with PNH already take medications known as C5 inhibitors that prevent red blood cells from breaking apart inside the blood vessels. However, some of these patients still experience extravascular hemolysis, which is when red blood cells are destroyed outside the blood vessels, typically in the spleen or liver.

Voydeya is used as an add-on treatment to address this specific problem. By blocking the complement system at an earlier stage, it helps prevent the immune system from marking red blood cells for destruction in the liver or spleen, which helps improve red blood cell counts and reduce symptoms like anemia.

Question 4

What are the active ingredients in Voydeya?

Accepted Answer

The active ingredient in Voydeya is danicopan.

Question 5

What are the side effects of Voydeya?

Accepted Answer

Common side effects of Voydeya may include:

Headache
Nausea
Diarrhea
Joint pain (arthralgia)
Pain in the arms or legs
Fever

Voydeya can cause serious health complications that require immediate medical attention. These include:

Serious Infections: This medication affects a part of the immune system, increasing the risk of life-threatening meningococcal infections. Seek emergency care if you experience a high fever, headache with a stiff neck, confusion, or a rash.
Liver Problems: Voydeya can cause an increase in liver enzymes, which may indicate liver stress or damage. Healthcare providers typically monitor liver function through regular blood tests during treatment.
Allergic Reactions: Although rare, serious allergic reactions can occur. Symptoms may include hives, swelling of the face or throat, and difficulty breathing.

This is not a complete list of potential side effects. Patients should report any new or worsening symptoms to their healthcare provider.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Voydeya?

Accepted Answer

Voydeya belongs to the IGF-1 receptor antagonist drug class.

Question 7

What is the dosage of Voydeya and how do I take it?

Accepted Answer

Administration Instructions

Voydeya is a tablet taken by mouth. It is typically taken three times a day, with or without food.

When taking this medication:

Swallow the tablets whole.
Do not crush, chew, or break the tablets.

Voydeya is used as an add-on therapy alongside other specific medications. Continue taking all medications in your treatment plan as directed by your healthcare provider.

Missed Dose

If you miss a dose, take it as soon as you remember. If it is nearly time for your next scheduled dose, skip the missed dose and resume your normal schedule. Do not take extra medicine to make up for a missed dose.

Question 8

Is Voydeya safe during pregnancy and breastfeeding?

Accepted Answer

There are no available data on the use of Voydeya in pregnant women to determine if there is a drug-associated risk of major birth defects, miscarriage, or other adverse outcomes. In animal reproduction studies, no evidence of fetal harm was observed at doses significantly higher than the maximum recommended human dose. However, animal studies do not always predict how a drug will affect a human pregnancy.

If you are pregnant or planning to become pregnant, you should discuss the potential benefits and risks of this medication with your healthcare provider.

It is not known whether Voydeya passes into human breast milk, how it affects milk production, or if it has any effect on a breastfed infant. Because of the potential for serious adverse reactions in a nursing child, it is recommended that individuals do not breastfeed while taking Voydeya and for at least 3 days after the final dose.

Question 9

What forms and strengths does Voydeya come in?

Accepted Answer

Available Forms

Voydeya is supplied as film-coated tablets for oral administration. These tablets are intended to be swallowed whole.

The medication is produced in different strengths, which are distinguished by their physical appearance, including color and specific markings on the tablet surface.

Question 10

What is the FDA approval status of Voydeya?

Accepted Answer

FDA Approval and Indication

The U.S. Food and Drug Administration (FDA) approved Voydeya (danicopan) in March 2024. It is indicated as an add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria (PNH).

Boxed Warning

Voydeya carries a boxed warning regarding the risk of serious and life-threatening infections caused by encapsulated bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type b. These infections can become fatal if not identified and treated quickly. Healthcare providers must ensure patients are vaccinated against these bacteria before starting treatment.

REMS Program

Due to the risk of serious infections, Voydeya is available only through a restricted program called the Voydeya Risk Evaluation and Mitigation Strategy (REMS). Requirements of this program include:

Prescribers must be certified by enrolling in the Voydeya REMS program.
Patients must be vaccinated against specific bacteria according to current medical guidelines at least two weeks before their first dose.
Patients must be informed of the signs of serious infection and must carry a Patient Safety Card at all times to alert medical professionals that they are taking this medication.

Question 11

What should I know about Voydeya and weight loss?

Accepted Answer

Weight Loss and Voydeya

Voydeya (danicopan) is a complement inhibitor used as an add-on treatment for adults with paroxysmal nocturnal hemoglobinuria (PNH). It is not indicated for weight loss, and there is no clinical evidence to suggest it is effective for weight management.

In clinical trials, researchers focused on the drug's ability to prevent the destruction of red blood cells. Weight changes were not reported as a common side effect or a primary outcome of the treatment. The most frequently reported side effects include:

Headache
Nausea
Diarrhea
Joint pain
Pain in the extremities

Because Voydeya is a specialized medication for a rare blood disorder, it should only be used for its FDA-approved purpose. If you experience significant or unexplained weight loss while taking this medication, you should contact a healthcare professional to investigate other potential causes.

Voydeya

📋Overview

How It Works

Uses

Active Ingredients

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

Found an Error?

Find Discounts for Voydeya

Hospitals.net Disclosure